Correction to “1H/15N NMR and Low-Field 1H MRI of SABRE-Hyperpolarized Pyrazinamide─An Approved Antibiotic and Potential MRI Contrast Agent”
The Journal of Physical Chemistry B · 18.11.2026
DOI: 10.1021/acs.jpcb.6c07383 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, online erschienen am 18.11.2026. Verfasst von Zahid Siraj und 10 weiteren Autor:innen. Gefördert von: Division of Chemistry, South Dakota School of Mines and Technology, Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Division of Chemistry
- South Dakota School of Mines and Technology
- Congressionally Directed Medical Research Programs
- National Institutes of Health
- Division of Materials Research
Zitieren
APA
Siraj, Z., Petrilla, A. F., Senanayake, I. M., Iqbal, N., Gyesi, J. N., Westerfield, J., Daluwathumullagamage, P. J., Shchepin, R. V., Ragunathan, S., Chekmenev, E. Y., & Goodson, B. M. (2026). Correction to “1H/15N NMR and Low-Field 1H MRI of SABRE-Hyperpolarized Pyrazinamide─An Approved Antibiotic and Potential MRI Contrast Agent”. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.6c07383
Vancouver
Siraj Z, Petrilla AF, Senanayake IM, Iqbal N, Gyesi JN, Westerfield J, et al. Correction to “1H/15N NMR and Low-Field 1H MRI of SABRE-Hyperpolarized Pyrazinamide─An Approved Antibiotic and Potential MRI Contrast Agent”. The Journal of Physical Chemistry B. 2026. doi:10.1021/acs.jpcb.6c07383
BibTeX
@article{Siraj2026,
author = {Siraj, Zahid and Petrilla, Anthony F. and Senanayake, Ishani M. and Iqbal, Nadiya and Gyesi, Joseph N. and Westerfield, Jasilyn and Daluwathumullagamage, Praveen J. and Shchepin, Roman V. and Ragunathan, Sudarshan and Chekmenev, Eduard Y. and Goodson, Boyd M.},
title = {Correction to “1H/15N NMR and Low-Field 1H MRI of SABRE-Hyperpolarized Pyrazinamide─An Approved Antibiotic and Potential MRI Contrast Agent”},
journal = {The Journal of Physical Chemistry B},
year = {2026},
doi = {10.1021/acs.jpcb.6c07383}
}
EUVIMED